Jounce Therapeutics Sinks on ASCO Update
Jounce Therapeutics watched its shares drop sharply on Monday after the company presented preliminary data from its early stage cancer trial at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.














